A5001865213- Cannabis and Cannabinoid Research
- Neurotransmitter Receptor Influence on Behavior
- Substance Abuse Treatment and Outcomes
- Forensic Toxicology and Drug Analysis
- Pain Mechanisms and Treatments
- Opioid Use Disorder Treatment
- Diet, Metabolism, and Disease
- Prenatal Substance Exposure Effects
- Homelessness and Social Issues
- Psychedelics and Drug Studies
- Sleep and Wakefulness Research
- Bipolar Disorder and Treatment
- Neuropeptides and Animal Physiology
- Alcohol Consumption and Health Effects
- Pain Management and Opioid Use
- GABA and Rice Research
- COVID-19 and Mental Health
- Neuroscience and Neuropharmacology Research
- Smoking Behavior and Cessation
- Food Security and Health in Diverse Populations
- Stress Responses and Cortisol
- Neuroscience of respiration and sleep
- Child and Adolescent Psychosocial and Emotional Development
- HIV, Drug Use, Sexual Risk
- Nicotinic Acetylcholine Receptors Study
University of California, Los Angeles
2019-2025
Neurobehavioral Systems
2020-2024
UCLA Medical Center
2024
Columbia University
2009-2023
British Columbia Centre on Substance Use
2022
Government of British Columbia
2022
Canadian Institutes of Health Research
2022
National Institutes of Health
2022
University of British Columbia
2022
St. Paul's Hospital
2022
Cannabis use disorder (CUD) is widespread, and there no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, signaling-specific inhibitor cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits subset intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice non-human primates, decreased self-administration THC-related behavioral impairment producing significant adverse effects....
ABSTRACT Background Sublingual buprenorphine is an effective maintenance treatment for opioid dependence, yet intravenous misuse occurs. A buprenorphine/naloxone formulation was developed to mitigate this risk. This randomized, double‐blind, cross‐over study conducted assess the abuse potential of compared with in buprenorphine‐maintained injection drug users (IDUs). Methods Intravenous heroin ( n = 12) lived hospital 8–9 weeks and were maintained on each three different sublingual doses (2...
Glial activation is hypothesized to contribute directly opioid withdrawal. This study investigated the dose-dependent effects of a glial cell modulator, ibudilast, on withdrawal symptoms in opioid-dependent volunteers after abrupt discontinuation morphine administration. Non-treatment-seeking heroin-dependent (n = 31) completed in-patient, double-blind, placebo-controlled, within-subject and between-group study. Volunteers were maintained (30 mg, QID) for 14 days placebo (0 last 7 3-week...
Background Ecological research suggests that increased access to cannabis may facilitate reductions in opioid use and harms, medical patients describe the substitution of opioids with for pain management. However, there is a lack using individual-level data explore this question. We aimed investigate longitudinal association between frequency illicit among people who drugs (PWUD) experiencing chronic pain. Methods findings This study included from 2 prospective cohorts PWUD Vancouver,...
Abstract Significant changes have occurred in the policy landscape surrounding cannabis legalization, production, and use around globe across United States. With widespread availability of novel cannabis-based products, there is an urgent need to understand their safety effectiveness for medical indications. Three primary barriers contribute difficulty initiating research geared toward answering most pressing public health questions: US regulatory status cannabinoids, sources cannabinoid...
Aims Preclinical studies demonstrate that cannabidiol (CBD) elicits an antinociceptive response in animal models of neuropathic pain; humans, limited data are available to support such analgesic effects. Few have examined CBD's effects when administered without other compounds, and little is known regarding dose‐dependent noncannabis users. Methods This double‐blind, placebo‐controlled, within‐subject outpatient clinical laboratory study sought determine the effects, abuse liability, safety...
Abstract Cannabigerol (CBG) is a phytocannabinoid increasing in popularity, with preclinical research indicating it has anxiolytic and antidepressant effects. However, there are no published clinical trials to corroborate these findings humans. The primary objective of this study was examine acute effects CBG on anxiety, stress, mood. Secondary objectives were whether produces subjective drug or motor cognitive impairments. A double-blind, placebo-controlled cross-over field trial conducted...
Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol poor bioavailability, potentially contributing its failure The synthetic THC analogue, nabilone, better bioavailability than dronabinol. We therefore aimed characterize nabilone's behavioral...
Opioid misuse and overuse have contributed to a widespread overdose crisis many patients physicians are considering medical cannabis support opioid tapering chronic pain control. Using five-step modified Delphi process, we aimed develop consensus-based recommendations on: 1) when how safely initiate titrate cannabinoids in the presence of opioids, 2) taper opioids 3) monitor evaluate outcomes treating with cannabinoids.